- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Florham Park Today
By the People, for the People
Celularity Receives Nasdaq Notice for Late 10-K Filing
Biotech firm working to complete and file annual report as soon as possible.
Apr. 20, 2026 at 7:03am
Got story updates? Submit your updates here. ›
The delayed filing of Celularity's annual report exposes the complex financial reporting challenges facing the regenerative medicine company.Florham Park TodayCelularity Inc., a regenerative medicine company, announced that it received a notice from Nasdaq regarding the late filing of its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company is working to complete and file the report as soon as practicable, but there is no guarantee it will be able to regain compliance within the time period granted by Nasdaq.
Why it matters
Timely filing of financial reports is a key requirement for companies listed on the Nasdaq exchange. Failure to meet this obligation can lead to delisting if not resolved, which would be a significant setback for Celularity as a publicly traded firm. The company's ability to regain compliance will be closely watched by investors and analysts.
The details
Celularity received the notice from Nasdaq on April 16, 2026, stating that it is not currently in compliance with the exchange's listing rule requiring timely filing of periodic financial reports. The company has 60 days to submit a plan to regain compliance, and Nasdaq may then grant an exception of up to 180 days from the original due date of the 10-K report for Celularity to file the document.
- Celularity received the Nasdaq notice on April 16, 2026.
- The company's 10-K report for fiscal year 2025 was originally due to be filed.
The players
Celularity Inc.
A longevity-focused regenerative and cellular medicine company developing allogeneic and autologous cell therapies derived from the postpartum placenta.
Nasdaq
The Nasdaq Stock Market LLC, which operates the Nasdaq exchange where Celularity's common stock and warrants are listed.
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
